Pelthos Therapeutics Inc. (PTHS)

Data as of Oct 6, 2026, from SEC Form 4 filings.

XASEBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Net insider selling (90d)Watch PTHS

See up to 3 months of PTHS. The 7-day demo opens the 1M and 3M ranges and puts PTHS on your watchlist.

Latest PTHS insider trades

Peter Greenleaf - Director
Open-market sale$17K
Oct 2, 2026
Ezra M. Friedberg - Director
Open-market sale$12K

About Pelthos Therapeutics Inc. (PTHS)

Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.

Headquarters: DURHAM, NC
Employees: 92
Listed: 2024
Exchange: XASE
Sector: Health Care

https://www.pelthos.com SEC filings for PTHS on EDGAR

PTHS Form 4 activity by transaction type, last 90 days

Form 4 transaction type	Transactions	Shares	Total value
Open-market sale	3	2,141	$45K

PTHS insider transactions (Form 4)

44 Form 4 filings on record, the earliest from Nov 15, 2024, newest first. Filing history page 1 of 2.

Date	Insider	Transaction	Security	Shares	Price	Value
Oct 2, 2026	Peter Greenleaf - Director	Open-market sale	Common Stock	797	$21.17	$17K
Oct 2, 2026	Ezra M. Friedberg - Director	Open-market sale	Common Stock	558	$20.72	$12K
Oct 2, 2026	Matthew Pauls - Director	Open-market sale	Common Stock	786	$21.00	$17K
Jul 2, 2026	Ezra M. Friedberg - Director	Open-market sale	Common Stock	534	$26.03^{footnote F2}	$14K
Jul 2, 2026	Ezra M. Friedberg - Director	Open-market sale	Common Stock	24	$27.33^{footnote F3}	$656
Footnote F2 (price): This transaction was executed in multiple trades at prices ranging from $25.58 to $26.24. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR Footnote F3 (price): This transaction was executed in multiple trades at prices ranging from $27.20 to $27.63. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR
Jul 2, 2026	Matthew Pauls - Director	Open-market sale	Common Stock	692	$26.00^{footnote F2}	$18K
Jul 2, 2026	Matthew Pauls - Director	Open-market sale	Common Stock	94	$27.36^{footnote F3}	$3K
Footnote F2 (price): This transaction was executed in multiple trades at prices ranging from $25.58 to $26.24. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR Footnote F3 (price): This transaction was executed in multiple trades at prices ranging from $27.20 to $27.63. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR
Jul 2, 2026	Peter Greenleaf - Director	Open-market sale	Common Stock	712	$26.00^{footnote F2}	$19K
Jul 2, 2026	Peter Greenleaf - Director	Open-market sale	Common Stock	85	$27.27^{footnote F3}	$2K
Footnote F2 (price): This transaction was executed in multiple trades at prices ranging from $25.58 to $26.53. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR Footnote F3 (price): This transaction was executed in multiple trades at prices ranging from $27.20 to $27.63. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR
Jun 15, 2026	Ezra M. Friedberg - Director	Open-market sale	Common Stock	224	$27.12^{footnote F2}	$6K
Jun 15, 2026	Ezra M. Friedberg - Director	Open-market sale	Common Stock	59	$27.94^{footnote F3}	$2K
Footnote F2 (price): This transaction was executed in multiple trades at prices ranging from $26.71 to $27.44. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR Footnote F3 (price): This transaction was executed in multiple trades at prices ranging from $27.92 to $28.00. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR
Jun 11, 2026	Todd C. Davis - Director	Open-market purchase	Common Stock	35,445	$27.80^{footnote F1}	$986K
Jun 11, 2026	Todd C. Davis - Director	Open-market purchase	Common Stock	503	$28.73^{footnote F2}	$14K
Footnote F1 (price): This transaction was executed in multiple trades at prices ranging from $27.63 to $28.49. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock purchased. The Reporting Person hereby undertakes to provide upon request to the SEC… Full note on SEC EDGAR Footnote F2 (price): This transaction was executed in multiple trades at prices ranging from $28.72 to $28.94. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock purchased. The Reporting Person hereby undertakes to provide upon request to the SEC… Full note on SEC EDGAR
May 22, 2026	Knuettel Francis II - Officer	Derivative	Common Stock	13,947^{footnote F1}	$0.00^{footnote F1}	-
May 22, 2026	Knuettel Francis II - Officer	Open-market sale	Common Stock	1,500^{footnote F3}	$26.84^{footnote F3}	$40K
May 22, 2026	Knuettel Francis II - Officer	Grant or award	Stock Option	59,500	-^{footnote F5}	-
May 22, 2026	Knuettel Francis II - Officer	Derivative	Stock Option	42,500	-^{footnote F6}	-
Footnote F1 (price, shares): Represents the forfeiture and cancellation of unvested restricted stock units ("RSUs") of Pelthos Therapeutics Inc. (the "Issuer"), for no consideration pursuant to that certain Separation Agreement entered into on May 15, 2026 (the "Separation Agreement") in connection with the… Full note on SEC EDGAR Footnote F3 (price, shares): Represents an open market sale of the Lara Knuettel Revocable (the "Trust") on May 22, 2026. This transaction was executed in multiple trades at prices ranging from $26.66 to $27.16. The price reported in column 4 above reflects the weighted average price of the shares of Common… Full note on SEC EDGAR Footnote F5 (price): Represents the acceleration of vesting of stock options pursuant to the Separation Agreement in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer. The unvested stock options became fully vested and exercisable on May 22… Full note on SEC EDGAR Footnote F6 (price): Represents the forfeiture and cancellation of unvested stock options for no consideration pursuant to the Separation Agreement in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer.
May 14, 2026	Ezra M. Friedberg - Director	Tax withholding / forfeiture	Common Stock	144	$27.01^{footnote F2}	$4K
Footnote F2 (price): This transaction was executed in multiple trades at prices ranging from $27.00 to $27.0101. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC… Full note on SEC EDGAR
Apr 2, 2026	Richard Malamut - Director	Open-market sale	Common Stock	310	$20.51^{footnote F2}	$6K
Apr 2, 2026	Richard Malamut - Director	Open-market sale	Common Stock	280	$21.36^{footnote F3}	$6K
Footnote F2 (price): This transaction was executed in multiple trades at prices ranging from $20.30 to $20.78. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR Footnote F3 (price): This transaction was executed in multiple trades at prices ranging from $21.31 to $22.03. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR
Apr 2, 2026	Ezra M. Friedberg - Director	Open-market sale	Common Stock	293	$20.51^{footnote F2}	$6K
Apr 2, 2026	Ezra M. Friedberg - Director	Open-market sale	Common Stock	265	$21.36^{footnote F3}	$6K
Footnote F2 (price): This transaction was executed in multiple trades at prices ranging from $20.30 to $20.78. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR Footnote F3 (price): This transaction was executed in multiple trades at prices ranging from $21.31 to $22.03. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR
Apr 2, 2026	Matthew Pauls - Director	Open-market sale	Common Stock	415	$20.52^{footnote F2}	$9K
Apr 2, 2026	Matthew Pauls - Director	Open-market sale	Common Stock	371	$21.36^{footnote F3}	$8K
Footnote F2 (price): This transaction was executed in multiple trades at prices ranging from $20.30 to $20.78. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR Footnote F3 (price): This transaction was executed in multiple trades at prices ranging from $21.31 to $22.03. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR
Apr 2, 2026	Peter Greenleaf - Director	Open-market sale	Common Stock	420	$20.52^{footnote F2}	$9K
Apr 2, 2026	Peter Greenleaf - Director	Open-market sale	Common Stock	377	$21.36^{footnote F3}	$8K
Footnote F2 (price): This transaction was executed in multiple trades at prices ranging from $20.30 to $20.78. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR Footnote F3 (price): This transaction was executed in multiple trades at prices ranging from $21.31 to $22.03. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR
Jun 14, 2024	Ezra M. Friedberg - Director	Grant or award	Common Stock	6,450	$0.00	-
Nov 13, 2024	Ezra M. Friedberg - Director	Grant or award	Common Stock	2,454	$0.00	-
Jul 2, 2025	Ezra M. Friedberg - Director	Grant or award	Common Stock	19,108	$0.00	-
Jun 14, 2024	Todd C. Davis - Director	Grant or award	Common Stock	12,900	$0.00	-
Nov 13, 2024	Todd C. Davis - Director	Grant or award	Common Stock	4,961	$0.00	-
Jul 2, 2025	Todd C. Davis - Director	Grant or award	Common Stock	19,108	$0.00	-
Jun 14, 2024	Richard Malamut - Director	Grant or award	Common Stock	6,450	$0.00	-
Nov 13, 2025	Richard Malamut - Director	Grant or award	Common Stock	2,454	$0.00	-
Jul 2, 2025	Richard Malamut - Director	Grant or award	Common Stock	19,108	$0.00	-
Jul 2, 2025	Scott M. Plesha - Officer	Grant or award	Common Stock	83,678	$0.00	-
Jul 2, 2025	Peter Greenleaf - Director	Grant or award	Common Stock	25,478	$0.00	-
Jul 2, 2025	Matthew Pauls - Director	Grant or award	Common Stock	25,478	$0.00	-
Jul 2, 2025	Sai Rangarao - Officer	Grant or award	Common Stock	30,518	$0.00	-
Jul 2, 2025	Richard B. Baxter - Director	Grant or award	Common Stock	19,108	$0.00	-
Jul 2, 2025	Knuettel Francis II - Officer	Grant or award	Common Stock	33,472	$0.00	-
Dec 23, 2025	Andrew J. Einhorn - Director	Grant or award	Common Stock	12,000	-^{footnote F1}	-
Footnote F1 (price): On December 23, 2025, the Reporting Person was granted 12,000 Restricted Stock Units (the "RSUs") of the issuer, as compensation for the Reporting Person's service as a member of the issuer's board of directors, pursuant to the issuer's 2023 Equity Incentive Plan, as amended and… Full note on SEC EDGAR
Dec 17, 2025	LIGAND PHARMACEUTICALS INC	Derivative	Senior Secured Convertible Note	0	-^{footnote F1,F2}	-
Dec 17, 2025	LIGAND PHARMACEUTICALS INC	Grant or award	Senior Secured Convertible Note	0	-^{footnote F1,F2}	-
Footnote F1 (price): On November 6, 2025, Pelthos Therapeutics Inc. (the "Issuer") entered into a Securities Purchase Agreement with the reporting person and certain other investors, pursuant to which the Issuer issued a senior secured convertible note (the "Convertible Note") in the aggregate… Full note on SEC EDGAR Footnote F2 (price): On December 17, 2025, at the annual meeting of the Issuer's shareholders, the Issuer's shareholders approved the waiver of the limit on the number of shares of Common Stock that may be issued to the holders of the Convertible Notes pursuant to the rules of the NYSE American LLC… Full note on SEC EDGAR
Jul 2, 2025	Matthew Pauls - Director	Option exercise	Common Stock	8,493^{footnote F1}	$0.00	-
Oct 2, 2025	Matthew Pauls - Director	Option exercise	Common Stock	2,123^{footnote F1}	$0.00	-
Dec 10, 2025	Matthew Pauls - Director	Gift	Common Stock	9,542^{footnote F2}	$0.00	-
Jul 2, 2025	Matthew Pauls - Director	Option exercise	Restricted Stock Units	8,493^{footnote F1}	$0.00	-
Oct 2, 2025	Matthew Pauls - Director	Option exercise	Restricted Stock Units	2,123^{footnote F1}	$0.00	-
Footnote F1 (shares): As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units ("RSUs"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a… Full note on SEC EDGAR Footnote F2 (shares): On December 10, 2025, the Reporting Person transferred 9,542 shares of Common Stock to GP 2024 Trust, U/A Dated, 12/20/2024, for no consideration. The Reporting Person is not a trustee and does not retain investment or voting control over the shares. Following the gift, the… Full note on SEC EDGAR
Nov 25, 2025	Ezra M. Friedberg - Director	Open-market sale	Common Stock	5,999	$28.00	$168K
Nov 25, 2025	Ezra M. Friedberg - Director	Open-market sale	Common Stock	2,000	$28.14	$56K
Nov 25, 2025	Ezra M. Friedberg - Director	Open-market sale	Common Stock	1	$28.50	$29
Nov 25, 2025	Ezra M. Friedberg - Director	Open-market sale	Common Stock	2,000	$28.01	$56K
Nov 6, 2025	LIGAND PHARMACEUTICALS INC	Grant or award	Senior Secured Convertible Note	0	$9,000,000.00^{footnote F1}	-
Footnote F1 (price): On November 6, 2025, Pelthos Therapeutics Inc. (the "Issuer") entered into a Securities Purchase Agreement with the reporting person and certain other investors, pursuant to which the Issuer issued a senior secured convertible note (the "Convertible Note") in the aggregate… Full note on SEC EDGAR
Jul 2, 2025	Sai Rangarao - Officer	Grant or award	Restricted Stock Units	30,518	-	-
Jul 2, 2025	Sai Rangarao - Officer	Grant or award	Stock Option	93,000	-	-
Jul 2, 2025	Richard B. Baxter - Director	Grant or award	Restricted Stock Units	19,108	-	-
Jul 2, 2025	Richard B. Baxter - Director	Grant or award	Stock Option	58,230	-	-

Recent PTHS Form 8-K filings

Read PTHS company news

Oct 1, 2026Item 5.02, 5.07, 9.01

Read the filing on SEC EDGAR

Aug 13, 2026Item 2.02, 7.01, 9.01

Read the filing on SEC EDGAR

Aug 13, 2026Item 4.02

Read the filing on SEC EDGAR

May 28, 2026Item 7.01, 9.01

Recent PTHS Form 144 notices of proposed sale

An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.

Filed	Filer	Relationship	Shares	Market value	Notice
May 22, 2026	-	-	-	-	View on EDGAR

PTHS insider trading FAQ

What is the latest insider trade for PTHS?

Pelthos Therapeutics Inc. (PTHS) had 3 insider filings in the last 90 days, with the most recent on 2026-10-06. The full record for PTHS runs to 44 Form 4 filings, the earliest from 2024-11-15. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.

How many insiders are buying PTHS stock?

No insider purchases of PTHS were filed in the last 90 days. 4 purchases are on record for this company.

How many insiders are selling PTHS stock?

3 insider sales of PTHS were filed in the last 90 days, totaling $45K.

Where can I see PTHS SEC filings (Form 4, 10-K, 10-Q, 8-K)?

This page collects PTHS Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.

More Health Care companies with insider activity

Recent insider filings

The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.

Oct 6, 2026 - Peter Greenleaf view on EDGAR
Oct 6, 2026 - Ezra M. Friedberg view on EDGAR
Oct 6, 2026 - Matthew Pauls view on EDGAR
Jul 7, 2026 - Ezra M. Friedberg view on EDGAR
Jul 7, 2026 - Matthew Pauls view on EDGAR
Jul 7, 2026 - Peter Greenleaf view on EDGAR
Jun 17, 2026 - Ezra M. Friedberg view on EDGAR
Jun 15, 2026 - Todd C. Davis view on EDGAR
May 26, 2026 - Knuettel Francis II view on EDGAR

Related companies with recent insider activity

Learn more

Insider selling: signal or noise?: Why most insider sales are routine, and the few patterns worth a second look.
Form 144 vs Form 4: A Form 144 announces a planned sale; the Form 4 reports it after it happens.
Insider activity in Health Care: Where PTHS's peers are being bought and sold.
Every recent Form 4: The market-wide feed, updated as filings arrive from SEC EDGAR.

Follow PTHS with a 7-day demo

PTHS on your watchlist
Every PTHS Form 4 filing on record
Up to 3 months of PTHS price history
The daily trading plan of ranked insider buys, on a delay, with the plan archive

Start 7-day demoCard required. Your card is never charged for the demo.

Form 4 transaction type

Transactions

Total value

Open-market sale

2,141

$45K

Date

Insider

Transaction

Security

Price

Value

Oct 2, 2026

Peter Greenleaf - Director

Open-market sale

Common Stock

797

$21.17

$17K

Oct 2, 2026

Ezra M. Friedberg - Director

Open-market sale

Common Stock

558

$20.72

$12K

Oct 2, 2026

Matthew Pauls - Director

Open-market sale

Common Stock

786

$21.00

$17K

Jul 2, 2026

Ezra M. Friedberg - Director

Open-market sale

Common Stock

534

$26.03^{footnote F2}

$14K

Jul 2, 2026

Ezra M. Friedberg - Director

Open-market sale

Common Stock

$27.33^{footnote F3}

$656

Footnote F2 (price): This transaction was executed in multiple trades at prices ranging from $25.58 to $26.24. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR
Footnote F3 (price): This transaction was executed in multiple trades at prices ranging from $27.20 to $27.63. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR

Jul 2, 2026

Matthew Pauls - Director

Open-market sale

Common Stock

692

$26.00^{footnote F2}

$18K

Jul 2, 2026

Matthew Pauls - Director

Open-market sale

Common Stock

$27.36^{footnote F3}

$3K

Footnote F2 (price): This transaction was executed in multiple trades at prices ranging from $25.58 to $26.24. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR
Footnote F3 (price): This transaction was executed in multiple trades at prices ranging from $27.20 to $27.63. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR

Jul 2, 2026

Peter Greenleaf - Director

Open-market sale

Common Stock

712

$26.00^{footnote F2}

$19K

Jul 2, 2026

Peter Greenleaf - Director

Open-market sale

Common Stock

$27.27^{footnote F3}

$2K

Footnote F2 (price): This transaction was executed in multiple trades at prices ranging from $25.58 to $26.53. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR
Footnote F3 (price): This transaction was executed in multiple trades at prices ranging from $27.20 to $27.63. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR

Jun 15, 2026

Ezra M. Friedberg - Director

Open-market sale

Common Stock

224

$27.12^{footnote F2}

$6K

Jun 15, 2026

Ezra M. Friedberg - Director

Open-market sale

Common Stock

$27.94^{footnote F3}

$2K

Footnote F2 (price): This transaction was executed in multiple trades at prices ranging from $26.71 to $27.44. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR
Footnote F3 (price): This transaction was executed in multiple trades at prices ranging from $27.92 to $28.00. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR

Jun 11, 2026

Todd C. Davis - Director

Open-market purchase

Common Stock

35,445

$27.80^{footnote F1}

$986K

Jun 11, 2026

Todd C. Davis - Director

Open-market purchase

Common Stock

503

$28.73^{footnote F2}

$14K

Footnote F1 (price): This transaction was executed in multiple trades at prices ranging from $27.63 to $28.49. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock purchased. The Reporting Person hereby undertakes to provide upon request to the SEC… Full note on SEC EDGAR
Footnote F2 (price): This transaction was executed in multiple trades at prices ranging from $28.72 to $28.94. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock purchased. The Reporting Person hereby undertakes to provide upon request to the SEC… Full note on SEC EDGAR

May 22, 2026

Knuettel Francis II - Officer

Derivative

Common Stock

13,947^{footnote F1}

$0.00^{footnote F1}

May 22, 2026

Knuettel Francis II - Officer

Open-market sale

Common Stock

1,500^{footnote F3}

$26.84^{footnote F3}

$40K

May 22, 2026

Knuettel Francis II - Officer

Grant or award

Stock Option

59,500

-^{footnote F5}

May 22, 2026

Knuettel Francis II - Officer

Derivative

Stock Option

42,500

-^{footnote F6}

Footnote F1 (price, shares): Represents the forfeiture and cancellation of unvested restricted stock units ("RSUs") of Pelthos Therapeutics Inc. (the "Issuer"), for no consideration pursuant to that certain Separation Agreement entered into on May 15, 2026 (the "Separation Agreement") in connection with the… Full note on SEC EDGAR
Footnote F3 (price, shares): Represents an open market sale of the Lara Knuettel Revocable (the "Trust") on May 22, 2026. This transaction was executed in multiple trades at prices ranging from $26.66 to $27.16. The price reported in column 4 above reflects the weighted average price of the shares of Common… Full note on SEC EDGAR
Footnote F5 (price): Represents the acceleration of vesting of stock options pursuant to the Separation Agreement in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer. The unvested stock options became fully vested and exercisable on May 22… Full note on SEC EDGAR
Footnote F6 (price): Represents the forfeiture and cancellation of unvested stock options for no consideration pursuant to the Separation Agreement in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer.

May 14, 2026

Ezra M. Friedberg - Director

Tax withholding / forfeiture

Common Stock

144

$27.01^{footnote F2}

$4K

Footnote F2 (price): This transaction was executed in multiple trades at prices ranging from $27.00 to $27.0101. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC… Full note on SEC EDGAR

Apr 2, 2026

Richard Malamut - Director

Open-market sale

Common Stock

310

$20.51^{footnote F2}

$6K

Apr 2, 2026

Richard Malamut - Director

Open-market sale

Common Stock

280

$21.36^{footnote F3}

$6K

Footnote F2 (price): This transaction was executed in multiple trades at prices ranging from $20.30 to $20.78. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR
Footnote F3 (price): This transaction was executed in multiple trades at prices ranging from $21.31 to $22.03. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR

Apr 2, 2026

Ezra M. Friedberg - Director

Open-market sale

Common Stock

293

$20.51^{footnote F2}

$6K

Apr 2, 2026

Ezra M. Friedberg - Director

Open-market sale

Common Stock

265

$21.36^{footnote F3}

$6K

Footnote F2 (price): This transaction was executed in multiple trades at prices ranging from $20.30 to $20.78. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR
Footnote F3 (price): This transaction was executed in multiple trades at prices ranging from $21.31 to $22.03. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR

Apr 2, 2026

Matthew Pauls - Director

Open-market sale

Common Stock

415

$20.52^{footnote F2}

$9K

Apr 2, 2026

Matthew Pauls - Director

Open-market sale

Common Stock

371

$21.36^{footnote F3}

$8K

Footnote F2 (price): This transaction was executed in multiple trades at prices ranging from $20.30 to $20.78. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR
Footnote F3 (price): This transaction was executed in multiple trades at prices ranging from $21.31 to $22.03. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR

Apr 2, 2026

Peter Greenleaf - Director

Open-market sale

Common Stock

420

$20.52^{footnote F2}

$9K

Apr 2, 2026

Peter Greenleaf - Director

Open-market sale

Common Stock

377

$21.36^{footnote F3}

$8K

Footnote F2 (price): This transaction was executed in multiple trades at prices ranging from $20.30 to $20.78. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR
Footnote F3 (price): This transaction was executed in multiple trades at prices ranging from $21.31 to $22.03. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff… Full note on SEC EDGAR

Jun 14, 2024

Ezra M. Friedberg - Director

Grant or award

Common Stock

6,450

$0.00

Nov 13, 2024

Ezra M. Friedberg - Director

Grant or award

Common Stock

2,454

$0.00

Jul 2, 2025

Ezra M. Friedberg - Director

Grant or award

Common Stock

19,108

$0.00

Jun 14, 2024

Todd C. Davis - Director

Grant or award

Common Stock

12,900

$0.00

Nov 13, 2024

Todd C. Davis - Director

Grant or award

Common Stock

4,961

$0.00

Jul 2, 2025

Todd C. Davis - Director

Grant or award

Common Stock

19,108

$0.00

Jun 14, 2024

Richard Malamut - Director

Grant or award

Common Stock

6,450

$0.00

Nov 13, 2025

Richard Malamut - Director

Grant or award

Common Stock

2,454

$0.00

Jul 2, 2025

Richard Malamut - Director

Grant or award

Common Stock

19,108

$0.00

Jul 2, 2025

Scott M. Plesha - Officer

Grant or award

Common Stock

83,678

$0.00

Jul 2, 2025

Peter Greenleaf - Director

Grant or award

Common Stock

25,478

$0.00

Jul 2, 2025

Matthew Pauls - Director

Grant or award

Common Stock

25,478

$0.00

Jul 2, 2025

Sai Rangarao - Officer

Grant or award

Common Stock

30,518

$0.00

Jul 2, 2025

Richard B. Baxter - Director

Grant or award

Common Stock

19,108

$0.00

Jul 2, 2025

Knuettel Francis II - Officer

Grant or award

Common Stock

33,472

$0.00

Dec 23, 2025

Andrew J. Einhorn - Director

Grant or award

Common Stock

12,000

-^{footnote F1}

Footnote F1 (price): On December 23, 2025, the Reporting Person was granted 12,000 Restricted Stock Units (the "RSUs") of the issuer, as compensation for the Reporting Person's service as a member of the issuer's board of directors, pursuant to the issuer's 2023 Equity Incentive Plan, as amended and… Full note on SEC EDGAR

Dec 17, 2025

LIGAND PHARMACEUTICALS INC

Derivative

Senior Secured Convertible Note

-^{footnote F1,F2}

Dec 17, 2025

LIGAND PHARMACEUTICALS INC

Grant or award

Senior Secured Convertible Note

-^{footnote F1,F2}

Footnote F1 (price): On November 6, 2025, Pelthos Therapeutics Inc. (the "Issuer") entered into a Securities Purchase Agreement with the reporting person and certain other investors, pursuant to which the Issuer issued a senior secured convertible note (the "Convertible Note") in the aggregate… Full note on SEC EDGAR
Footnote F2 (price): On December 17, 2025, at the annual meeting of the Issuer's shareholders, the Issuer's shareholders approved the waiver of the limit on the number of shares of Common Stock that may be issued to the holders of the Convertible Notes pursuant to the rules of the NYSE American LLC… Full note on SEC EDGAR

Jul 2, 2025

Matthew Pauls - Director

Option exercise

Common Stock

8,493^{footnote F1}

$0.00

Oct 2, 2025

Matthew Pauls - Director

Option exercise

Common Stock

2,123^{footnote F1}

$0.00

Dec 10, 2025

Matthew Pauls - Director

Gift

Common Stock

9,542^{footnote F2}

$0.00

Jul 2, 2025

Matthew Pauls - Director

Option exercise

Restricted Stock Units

8,493^{footnote F1}

$0.00

Oct 2, 2025

Matthew Pauls - Director

Option exercise

Restricted Stock Units

2,123^{footnote F1}

$0.00

Footnote F1 (shares): As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units ("RSUs"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a… Full note on SEC EDGAR
Footnote F2 (shares): On December 10, 2025, the Reporting Person transferred 9,542 shares of Common Stock to GP 2024 Trust, U/A Dated, 12/20/2024, for no consideration. The Reporting Person is not a trustee and does not retain investment or voting control over the shares. Following the gift, the… Full note on SEC EDGAR

Nov 25, 2025

Ezra M. Friedberg - Director

Open-market sale

Common Stock

5,999

$28.00

$168K

Nov 25, 2025

Ezra M. Friedberg - Director

Open-market sale

Common Stock

2,000

$28.14

$56K

Nov 25, 2025

Ezra M. Friedberg - Director

Open-market sale

Common Stock

$28.50

$29

Nov 25, 2025

Ezra M. Friedberg - Director

Open-market sale

Common Stock

2,000

$28.01

$56K

Nov 6, 2025

LIGAND PHARMACEUTICALS INC

Grant or award

Senior Secured Convertible Note

$9,000,000.00^{footnote F1}

Footnote F1 (price): On November 6, 2025, Pelthos Therapeutics Inc. (the "Issuer") entered into a Securities Purchase Agreement with the reporting person and certain other investors, pursuant to which the Issuer issued a senior secured convertible note (the "Convertible Note") in the aggregate… Full note on SEC EDGAR

Jul 2, 2025

Sai Rangarao - Officer

Grant or award

Restricted Stock Units

30,518

Jul 2, 2025

Sai Rangarao - Officer

Grant or award

Stock Option

93,000

Jul 2, 2025

Richard B. Baxter - Director

Grant or award

Restricted Stock Units

19,108

Jul 2, 2025

Richard B. Baxter - Director

Grant or award

Stock Option

58,230

Filed

Filer

Relationship

Market value

Notice

May 22, 2026

View on EDGAR